Contribution: Industrial Research Assistance Program – Contributions to Firms
Maresins Pharma, inc.
$83,372.00
Maximisation of a topical formulation containing an analog of Maresin-1 (MaR102) to treat pain and inflammation in an animal model of Vulvodynia
FY 2019-20 · 2019-10-15
Summary
Several published studies have shown the high potency of MaR1 to decrease pain and inflammation in various animal models. The goal of the current project is to demonstrate and improve the capacity of a specific topical formulation containing a synthetic analog of MaR1 to decrease pain and inflammation in a relevant rodent model of vulvodynia.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Quebec|Québec, Quebec, Canada
Recipient Type
For-profit organization
Business Number
806535035
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-10-15 | 2019-20 | $73,572.00 |
| 1 | 2019-10-15 | 2019-20 | $73,572.00 |
| 2 | 2019-10-15 | 2019-20 | $83,372.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 9,800 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 9 800 dollars.
Agreement End Date
2020-12-31
Agreement Number
936187
Agreement Start Date
2019-10-15
Agreement Title
Maximisation of a topical formulation containing an analog of Maresin-1 (MaR102) to treat pain and inflammation in an animal model of Vulvodynia
Agreement Title (French)
Maximisation d'une formule topique renfermant un analogue de Maresin-1 (MaR102) pour traiter la douleur et l'inflammation dans un modèle de vulvodynie chez un animal.
Agreement Type
Contribution
Agreement Value
$83,372.00
Amendment Date
2020-11-09
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Several published studies have shown the high potency of MaR1 to decrease pain and inflammation in various animal models. The goal of the current project is to demonstrate and improve the capacity of a specific topical formulation containing a synthetic analog of MaR1 to decrease pain and inflammation in a relevant rodent model of vulvodynia.
Description (French)
Plusieurs études publiées ont démontré la puissance supérieure de MaR1 pour diminuer la douleur et l'inflammation chez divers types d'animaux. Le but du projet actuel est de démontrer et d'améliorer la capacité d'une formule topique particulière, renfermant un analogue synthétique de MaR1, de diminuer la douleur et l'inflammation dans un modèle pertinent de vulvodynie chez le rongeur.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Louis-Hébert
Federal Riding (French)
Louis-Hébert
Federal Riding Number
24044
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
806535035
Recipient City
Quebec|Québec
Recipient Country
CA
Recipient Legal Name
Maresins Pharma, inc.
Recipient Postal Code
G1V 0B9
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2019-2020-Q3-936187
